Roche drops Alzheimer drug trials after setback

Roche drops Alzheimer drug trials after setbackThe announcement by Roche, which has been working on the product with Swiss-based partner AC Immune, marks the latest high-profile failure of Alzheimer's disease drugs following the 2016 flop of an experimental medicine from Eli Lilly, among others. Roche said an Alzheimer's Prevention Initiative (API) study of crenezumab in familial Alzheimer's disease in Colombia would continue and that it remained committed to ongoing clinical studies in Alzheimer's disease, including separate phase-III trials with gantenerumab and a phase-II anti-tau trial that seek to tackle the debilitating brain-wasting sickness. AC Immune Chief Executive Andrea Pfeifer said the company was "extremely disappointed" by the news, adding that she was still hopeful the study in Colombia -- focusing on cognitively healthy individuals with a genetic mutation who are at risk of developing Alzheimer's disease -- would turn out more positively.




from Yahoo News - Latest News & Headlines https://yhoo.it/2CSSnVB
via IFTTT

Comments

Popular posts from this blog

Trump says he’ll spare Chinese telecom firm ZTE from collapse, defying lawmakers – Washington Post

'The Walking Dead' will return for Season 9 with a familiar face as the new showrunner